Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

iTeos Therapeutics, Inc. (ITOS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
20.39-0.73 (-3.46%)
At close: 04:00PM EST
20.39 0.00 (0.00%)
After hours: 04:01PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close21.12
Open21.01
Bid20.58 x 800
Ask20.62 x 1000
Day's Range20.28 - 21.31
52 Week Range16.21 - 37.88
Volume221,359
Avg. Volume336,931
Market Cap719.235M
Beta (5Y Monthly)1.55
PE Ratio (TTM)51.10
EPS (TTM)0.40
Earnings DateMar 21, 2023 - Mar 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.75
  • GlobeNewswire

    iTeos Provides Business Updates and Clinical Development Plans for 2023

    - 2023 will produce significant advances for both anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant - Eleven clinical trials planned or ongoing against multiple tumor types, across three pipeline programs - EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway, expected to enter clinical studies mid-2023 - Cash balance of $752MM as of September 30, 2022, expected to provide runway into 2026 through multip

  • GlobeNewswire

    iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Tuesday, January 10, 2023 at 8:15 a.m. PST (11:15 a.m. EST).

  • Simply Wall St.

    Could The Market Be Wrong About iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Its Attractive Financial Prospects?

    iTeos Therapeutics (NASDAQ:ITOS) has had a rough three months with its share price down 8.4%. But if you pay close...

Advertisement
Advertisement